Stream
Stories
-
Specific Biologics announces oversubscribed US$35 million Series A financing
Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations and other investors. The proceeds will be used to advance the lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS.
-
FDA issues final guidance for cell and gene therapy manufacturers
The FDA today issued final guidance for cellular and gene therapy (CGT) manufacturers, replacing its 2011 potency testing guidance and recommending a Potency Assurance Strategy for products treating serious or life-threatening conditions. The FDA will host a webinar on December 10, 2026 to help stakeholders understand and implement the guidance.
-
Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma
The study, led by Keymed Biosciences Co.Ltd, plans to enroll 320 participants and start in December 2026. It compares CM336+CM313 with Daratumumab+Pomalidomide+Dexamethasone in patients who have received 1 to 3 prior lines of therapy.
-
Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer
Merck Sharp & Dohme LLC has registered a Phase 3 randomized study to evaluate the safety and efficacy of Gocatamig (MK-6070) with Durvalumab versus Durvalumab alone as consolidation therapy in limited-stage small cell lung cancer. The trial plans to enroll 564 participants and is expected to start on December 7, 2026.
-
Guangzhou Patronus registers Phase III trial of LYB005 RSV vaccine in older adults
The Guangzhou Patronus Biotech Co., Ltd. study plans to enroll an estimate of 25000 participants aged 60 years and older, with a planned start date of November 2026 and a planned primary completion date of September 2027. The trial is randomized, observer-blind, and placebo-controlled.
-
Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes
The company posted results of a completed Phase 3 study that enrolled 617 participants with heart failure with preserved ejection fraction and type 2 diabetes, comparing semaglutide 2.4 mg once-weekly to a dummy medicine. The trial began on June 15 2021 and reached primary completion on October 11 2023.
-
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Fresenius SE & Co. KGaA announced an exclusive development agreement with WuXi Biologics that gives Fresenius access to up to 37 identified biosimilar candidates over the next decade, potentially expanding its portfolio from 29 to up to 66 molecules. The agreement, the largest in the biosimilars industry to date, preserves Fresenius' full commercialization economics and strategic flexibility.
-
Abbott reports strong 30-day outcomes in TECTONIC IVL study
The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.
-
FDA proposes changes to infant formula nutrient specifications and labeling
The FDA proposes to amend the minimum and/or maximum levels of iodine, vitamin A, vitamin D, and manganese, change the unit of measure for vitamin A from IU to microgram Retinol Activity Equivalents and for vitamin D from IU to micrograms, and modify labeling requirements. Comments on the rule are due by March 2, 2027.
-
CMS final rule clarifies oversight of Organ Procurement Organizations
The Centers for Medicare & Medicaid Services published a final rule that clarifies recertification, competition, and appeals processes for Organ Procurement Organizations. The rule defines unsound medical practices and requires OPOs to have QAPI programs to monitor adverse events.
-
FDA approves first plasmid DNA-based immunotherapy for adults with RRP
The FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV. In an open-label multicenter trial of 32 adults, 27% of patients who had at least three baseline surgeries did not require any surgery during the first year after treatment.
-
Boehringer Ingelheim registers Phase III trial of verducatib in COPD
The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.